Research Comparison
Cagrilintide (AM833) vs Survodutide (BI 456906)
A side-by-side research comparison of Cagrilintide (AM833) and Survodutide (BI 456906) drawn from Cobalt Peptides' peptide database records.
Cagrilintide (AM833)
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.
Survodutide (BI 456906)
Survodutide (BI 456906) is an investigational dual glucagon receptor and GLP-1 receptor agonist. It is a 29-amino acid peptide with C18 fatty acid acylation, a modification that extends its duration of action and supports once-weekly administration in study protocols. Its dual mechanism engages both receptors rather than one, and is the subject of ongoing published research. Survodutide is not an approved medicine. Supplied strictly as a research compound for laboratory use.